- Home
- IOTR vs KALA Comparison
IOTR vs KALA Comparison
Compare IOTR & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOTR
- KALA
- Stock Information
- Founded
- IOTR 2019
- KALA 2009
- Country
- IOTR Singapore
- KALA United States
- Employees
- IOTR N/A
- KALA N/A
- Industry
- IOTR
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- IOTR
- KALA Health Care
- Exchange
- IOTR NYSE
- KALA Nasdaq
- Market Cap
- IOTR 29.5M
- KALA 26.2M
- IPO Year
- IOTR 2025
- KALA 2017
- Fundamental
- Price
- IOTR $0.41
- KALA $5.26
- Analyst Decision
- IOTR
- KALA Strong Buy
- Analyst Count
- IOTR 0
- KALA 3
- Target Price
- IOTR N/A
- KALA $14.00
- AVG Volume (30 Days)
- IOTR 465.4K
- KALA 55.9K
- Earning Date
- IOTR 01-01-0001
- KALA 08-05-2025
- Dividend Yield
- IOTR N/A
- KALA N/A
- EPS Growth
- IOTR N/A
- KALA N/A
- EPS
- IOTR N/A
- KALA N/A
- Revenue
- IOTR $9,578,336.00
- KALA N/A
- Revenue This Year
- IOTR N/A
- KALA N/A
- Revenue Next Year
- IOTR N/A
- KALA N/A
- P/E Ratio
- IOTR N/A
- KALA N/A
- Revenue Growth
- IOTR 13.93
- KALA N/A
- 52 Week Low
- IOTR $0.31
- KALA $2.92
- 52 Week High
- IOTR $5.98
- KALA $11.20
- Technical
- Relative Strength Index (RSI)
- IOTR N/A
- KALA 68.75
- Support Level
- IOTR N/A
- KALA $3.82
- Resistance Level
- IOTR N/A
- KALA $4.41
- Average True Range (ATR)
- IOTR 0.00
- KALA 0.42
- MACD
- IOTR 0.00
- KALA 0.07
- Stochastic Oscillator
- IOTR 0.00
- KALA 92.00
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.